Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Saroglitazar by Zydus Therapeutics for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Likelihood of Approval
Saroglitazar is under clinical development by Zydus Therapeutics and currently in Phase II for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)....
Saroglitazar by Zydus Therapeutics for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
Saroglitazar is under clinical development by Zydus Therapeutics and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to...
Saroglitazar by Zydus Therapeutics for Cholestasis: Likelihood of Approval
Saroglitazar is under clinical development by Zydus Therapeutics and currently in Phase I for Cholestasis. According to GlobalData, Phase I...
Saroglitazar by Zydus Therapeutics for Primary Sclerosing Cholangitis: Likelihood of Approval
Saroglitazar is under clinical development by Zydus Therapeutics and currently in Phase I for Primary Sclerosing Cholangitis. According to GlobalData,...
Saroglitazar by Zydus Therapeutics for Liver Diseases: Likelihood of Approval
Saroglitazar is under clinical development by Zydus Therapeutics and currently in Phase I for Liver Diseases. According to GlobalData, Phase...
Saroglitazar by Zydus Therapeutics for Primary Biliary Cholangitis (Primary Biliary Cirrhosis): Likelihood of Approval
Saroglitazar is under clinical development by Zydus Therapeutics and currently in Phase III for Primary Biliary Cholangitis (Primary Biliary Cirrhosis)....
Saroglitazar by Zydus Lifesciences for Hypertriglyceridemia: Likelihood of Approval
Saroglitazar is under clinical development by Zydus Lifesciences and currently in Phase II for Hypertriglyceridemia. According to GlobalData, Phase II...